Showing results (371-380 of 432) with videos related to

Sort By:
Pageof 44
Hemasphere|May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.
The New England Journal of Medicine|August 14, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D DiNardo, Brian A Jonas, Vinod Pullarkat, et al.
NEJM Evidence|May 26, 2026
Prognostic Score for Myelodysplastic Syndromes Based on Molecular EvolutionIvan Civettini, Federica Malighetti, Matteo Villa, et al.
British Journal of Haematology|April 4, 2018
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registriesMaría Díez-Campelo, Jose I Lorenzo, Raphael Itzykson, et al.
Haematologica|July 7, 2019
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registryMarlijn Hoeks, Ge Yu, Saskia Langemeijer, et al.
Blood Advances|August 26, 2020
Guideline-based indicators for adult patients with myelodysplastic syndromesKristina Stojkov, Tobias Silzle, Georg Stussi, et al.
The Lancet. Haematology|October 28, 2023
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMTCarmelo Gurnari, Marie Robin, Lucy A Godley, et al.
International Journal of Molecular Sciences|April 20, 2017
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational StudyAntonio M Almeida, Thomas Prebet, Raphael Itzykson, et al.
Cancer Discovery|July 24, 2021
Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML TherapyHsin-Chieh Wu, Domitille Rérolle, Caroline Berthier, et al.
Nature Communications|February 25, 2016
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agentsJane Merlevede, Nathalie Droin, Tingting Qin, et al.
Pageof 44